Overview


According to FutureWise analysis the market for antithrombin is expected to reach US$ 0.89 billion by 2031 at a CAGR of 4.30%.

Antithrombin, a glycoprotein manufactured in the liver, stands as a fundamental element within the complex haemostatic system of the body. Its primary role is regulating the coagulation cascade to prevent excessive clot formation. As a serine protease inhibitor, antithrombin neutralizes key enzymes critical for coagulation, most notably thrombin (factor IIa) and factor Xa. Antithrombin curbs their activity by forming inhibitory complexes with these enzymes, effectively impeding the conversion of fibrinogen to fibrin and the subsequent assembly of stable blood clots. 

Hereditary deficiencies in antithrombin are associated with an increased susceptibility to thrombotic disorders. This highlights its indispensable function in maintaining the delicate equilibrium between bleeding and clotting. In clinical medicine, antithrombin plays a pivotal role in preventing and treating thrombotic events. Conditions such as deep vein thrombosis (DVT), pulmonary embolism (PE), and disseminated intravascular coagulation (DIC) can be managed by modulating antithrombin activity. From a therapeutic perspective, antithrombin concentrates derived from human plasma or recombinant technologies have emerged as valuable tools. These concentrates, containing purified antithrombin, are administered to patients to supplement their endogenous anticoagulant defences. This approach is particularly crucial for individuals with congenital antithrombin deficiency or those undergoing high-risk surgeries with elevated potential for thrombosis. Antithrombin concentrates help mitigate the risk of thrombosis and its associated complications by bolstering the body's natural anticoagulant mechanisms.

FutureWise Market Research has published a report that provides an insightful analysis of Antithrombin Market trends that are affecting the overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes stature of key manufacturers operational in this industry. By the end of the forecast period FutureWise research analysts’ projects that Antithrombin Market will experience a significant growth. According to the analysis done, this report will help understand the information referring to the total valuation held by this industry. Additionally, this report will help in understanding the growth opportunities held by various segments of this market, further assist in making better strategic and expansion decisions by key stakeholders of an organization.

  • CSL Limited
  • Grifols S.A
  • Takeda Pharmaceutical Company Limited
  • Octapharma AG
  • LFB USA
  • Axis-Shield Plc
  • Siemens AG
  • Thermo Fisher Scientific
  • Lee Biosolutions Inc.
  • REVO Biologics, Inc.
  • Kedrion S.p.A
  • Dem ilac Inc.
  • Diapharma
  • Scripps Laboratories, Inc.

(Note: The list of the major players will be updated with the latest market scenario and trends)

Recent Development in Antithrombin Market

  • In February 2022, Grifols initiated a partnership with Endpoint Health, Inc. to jointly create and bring to market a therapeutic solution involving Antithrombin III (AT-III) to address the condition of Sepsis. Within the framework of this agreement, Grifols is set to contribute its extensive expertise in plasma-protein therapies and will hold the exclusive role of supplying AT-III, a plasma protein renowned for its efficacy in treating individuals with blood coagulation disorders.

  • During the same month, specifically in February 2022, Techdow USA Inc., a fully integrated company specializing in generic injectable pharmaceuticals, unveiled its Heparin Sodium Injection, USP, within the United States market.

The antithrombin market is propelled by intricate drivers and opportunity that collectively shape its trajectory. The gradual surge in thrombotic disorders, encompassing critical conditions such as pulmonary embolism (PE)and deep vein thrombosis (DVT), is a formidable driver. As these disorders continue to pose substantial health risks, the demand for effective antithrombin therapies that can prevent and treat these life-threatening events experiences a pronounced upswing. In parallel, the progressive aging of the global population contributes significantly to the market's expansion. The heightened vulnerability of older people to thrombotic events due to factors like decreased mobility and heightened comorbidities necessitates advanced antithrombin treatments to mitigate these risks.

However, this growth has its challenges. Intensified competition from a diverse array of alternative anticoagulant and antiplatelet therapies imparts a degree of restraint on the antithrombin market. Considering varying mechanisms of action and safety profiles necessitates a holistic evaluation beyond the purview of antithrombin therapies alone. Furthermore, the specter of potential side effects and safety concerns accompanying any therapeutic intervention can impact market penetration. Striking a delicate balance between the undeniable benefits of preventing thrombotic events and the associated risks becomes pivotal. Financial considerations also cast a shadow, with the cost of antithrombin therapies often substantial. This financial burden can impede broader patient access, particularly in regions with stringent healthcare budgets or inadequate insurance coverage. The intricate path of drug development, characterized by its demands for research investments, comprehensive preclinical studies, and complex clinical trials, can pose hurdles. Regulatory complexities and the ever-present possibility of setbacks within the development process contribute to challenges that must be navigated adeptly.

By Usage

  • Therapeutics
  • Diagnostics
  • Research
  • Other

By Source

  • Human
  • Recombinant Goat milk
  • Others

By Type

  • Anticoagulant
  • Antiplatelet
  • Thrombolytic Drugs

By Route

  • Oral
  • Parenteral

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

This market research report also emphasis on factors affecting the growth rate in various regions listed above. A deep-down analysis of region will also be provided in the final version of this market which is based on conclusion of primary interviews and secondary data point gathered during the process.

By region, the market is segmented into North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa. In the Antithrombin Market, the Asia-Pacific region is poised for significant growth due to the adoption of advanced medical treatments in developing nations like India and China to combat various diseases. The expanding disposable incomes in these countries and a greater capacity to invest in advanced healthcare solutions create a wealth of opportunities within the Asia-Pacific market. Additionally, the mounting challenges posed by aging populations, an uptick in thrombosis-related conditions, and fresh research into antithrombin deficiency are critical drivers of market growth in the foreseeable future. Moreover, ongoing research into antithrombin deficiency in the area is anticipated to bolster the availability of antithrombin products and catalyze market expansion. These insights into antithrombin deficiency are anticipated to drive the adoption of specialized diagnostic products, stimulating market growth in the projected period.

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the Antithrombin Market By Usage, By Source, By Type, By Route and By Region.
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape mapping- Usage launches, technological advancements, mergers and expansions

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders

  • 2.   Research Sourceology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study

  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Antithrombin Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Antithrombin Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Antithrombin Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Antithrombin Market, By Usage Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Therapeutics
        2. Diagnostics
        3. Research
        4. Other

  • 8.   Antithrombin Market, By Source Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Human
        2. Recombinant Goat milk
        3. Others

  • 9.   Antithrombin Market, By Type Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Anticoagulant
        2. Antiplatelet
        3. Thrombolytic Drugs

  • 10.   Antithrombin Market, By Route Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Oral
        2. Parenteral

  • 11.   North America Antithrombin Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 12.   Latin America Antithrombin Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 13.   Europe Antithrombin Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 14.   Asia Pacific Antithrombin Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 15.   Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 16.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 17.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Usages Offered and Financial Layouts)
    •   1. CSL Limited
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Grifols S.A
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Takeda Pharmaceutical Company Limited
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Octapharma AG
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. LFB USA
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Axis-Shield Plc
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. Siemens AG
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. Thermo Fisher Scientific
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. Lee Biosolutions Inc.
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10. REVO Biologics, Inc..
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview
        11. Kedrion S.p.A
         11.1. Company Overview
         11.2. Product Portfolio
         11.3. SWOT Analysis
         11.4. Financial Overview
         11.5. Strategic Overview
        12. Dem ilac Inc.
         12.1. Company Overview
         12.2. Product Portfolio
         12.3. SWOT Analysis
         12.4. Financial Overview
         12.5. Strategic Overview
        13. Diapharma
         13.1. Company Overview
         13.2. Product Portfolio
         13.3. SWOT Analysis
         13.4. Financial Overview
         13.5. Strategic Overview
        14. Scripps Laboratories, Inc.
         14.1. Company Overview
         14.2. Product Portfolio
         14.3. SWOT Analysis
         14.4. Financial Overview
         14.5. Strategic Overview

  • 18.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by administrations
        5. The overall economic slowdown of the developing and developed nations
  • 19.   FutureWise SME Key Takeaway Points for Client
Partner

Our Clients